

BIOGRAPHICAL SKETCH

Complete for each professional associated with the project

Name: <i>[Last, First, Middle Initial(s), Degree(s)]</i> ALBERTO GAJOFATTO, MD, PhD	Position/Title: ASSISTANT PROFESSOR OF NEUROLOGY
--	--

Education

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
Liceo Scientifico A. Messedaglia, Verona, Italy	B.S.	1997	sciences
University of Verona, Italy	MD	2003	Medicine
University of Verona, Italy	Neurology Specialty	2008	Neurology
University of Verona, Italy	PhD	2012	Neuroscience

Research and Professional Experience

[List in chronological order, previous employment, experience and honors]

PROFESSIONAL and RESEARCH TRAINING/PAST POSITIONS:

Policlinico G.B. Rossi, University of Verona:
Medical Internship: 2002 – 2003

Policlinico G.B. Rossi, University of Verona:
Residency in Neurology: 2003 – 2008

UCSF Multiple Sclerosis Center, San Francisco, CA:
Postdoctoral Fellowship: 2006 – 2007

Department of Neurological Sciences, University of Verona:
PhD Program in Neuroscience: 2009 – 2011

Policlinico G.B. Rossi, Neurology Department, Multiple Sclerosis Center, Verona:
Clinical Fellowship: 2008 – 2013

RESEARCH PROJECTS DEvised AND MANAGED

- Role of serum anti-aquaporin-4 and anti-MOG antibodies in the diagnosis of atypical demyelinating syndromes; 2016 –
- Validation of 2010 McDonald's criteria for primary progressive multiple sclerosis; 2015 –
- Brain functional MRI changes in multiple sclerosis patients with spasticity; 2014 –
- Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis; 2013 –
- Natural history study of untreated benign multiple sclerosis patients; 2013 –
- Clinical and cognitive evolution of multiple sclerosis with benign course: a 5-year prospective study; 2013-2014
- Natalizumab or fingolimod as second-line options for relapsing-remitting multiple sclerosis: an observational study; 2012 – 2014
- Exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS; 2009 – 2012
- Predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis; 2007 – 2008
- Impact of switching first-line disease-modifying therapy after treatment failure in relapsing-remitting multiple sclerosis; 2006 – 2007

AWARDS AND PRIZES

- Young Investigator Award for Multiple Sclerosis Research 2013; European Charcot Foundation 21st Annual Meeting; Baveno, 28-30 November 2013
- Neuroimmunology and Demyelinating Diseases Special Interest Group; American Neurological Association 134th Annual Meeting; Baltimore, 11-14 October 2009

COLLABORATIONS

- IstitutoSuperiore di Sanità: molecular markers of cortical pathology in multiple sclerosis; 2013 –
- RiReMS group: rising researchers in multiple sclerosis; 2013 –
- UCSF Multiple Sclerosis Center, University of California San Francisco; 2006 –

PARTICIPATION IN MULTICENTER STUDIES AND CLINICAL TRIALS

- Beta-interferon in Early relapsing-remitting multiple sclerosis Surveillance Trial (*MultScler* 2007; 13: S49)
- GERONIMUS Study (Gruppo Emiliano-ROMagnolo Neurologi In MultipleSclerosis) (*Eur J Neurol* 2009; 16, Suppl 3: 245)
- MAIN trial (*Neuroepidemiology* 2009; 33: 197)
- CFTY720D2316: A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis.

- BD0109: Relationship between IL-6 and TNF- α polymorphism with flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1 a im
- CFTY720D2399: A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis
- NGM114840: A randomized, single blind, placebo-controlled, single ascending dose/repeat dose cohort study to assess safety, tolerability, pharmacokinetics and immunogenicity of GSK1223249 in patients with relapsing forms of multiple sclerosis
- CFTY720DIT03: An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists
- EFC6058 – Teracles: A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta

TEACHING

- Neurology; Nursing School, University of Verona, 2015 –
- Demyelinating diseases; Residency Program in Neurology, University of Verona; 2015 –
- Neurology (practical training); School of Medicine, University of Verona, 2014 –

Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. *MultScler*.2009; 15:50-58

Gajofatto A, Monaco S, Fiorini M, Zanusso G, Vedovello M, Rossi F, Turatti M, Benedetti MD. Assessment of outcome predictors in first-ever acute myelitis: a retrospective study on 53 cases. *Arch Neurol*. 2010; 67:724-730

Castillo-Trivino T, Mowry EM, **Gajofatto A**, Chabas D, Crabtree-Hartman E, Cree B, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. **Switching multiple sclerosis patients with breakthrough disease to second-line therapy. *Plos One* 2011; 6(2):e16664**

Invernizzi P, Bertolasi L, Turatti M, Bianchi MR, **Gajofatto A**, Benedetti MD. **Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. *J Neurol*. 2011; 258:1933-1939**

Turatti M, **Gajofatto A**, Bianchi MR, Ferrari S, Monaco S, Benedetti MD. **Benign course of tumour-like multiple sclerosis: report of five cases and literature review. *J Neurol Sci*. 2013; 324(1-2):156-62**

Gajofatto A, Stefani A, Turatti M, et al. Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study. *Eur J Neurol*. 2013; 20(4):697-703

Gajofatto A, Bongiani M, Zanusso G, et al. Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. *Acta NeurolScand*. 2013; 128:336-344

Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. *Dis Markers* 2013;35(6):687-99

Gajofatto A, Bianchi MR, Deotto L, Benedetti MD. Are Natalizumab and Fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. *EurNeurol*.2014;72:173-180

Calabrese M, **Gajofatto A**, Gobbin F, et al. **Late-onset multiple sclerosis presenting with cognitive dysfunction and cortical/infratentorial atrophy. *MultScler*. 2015;21(5):580-89**

Gandolfi M, Munari D, Geroin C, et al. **Sensory integration balance training in patients with multiple sclerosis: a randomized, controlled trial. *MultScler*. 2015 Oct;21(11):1453-62**

Gajofatto A, Turatti M, Bianchi MR, et al. Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions. *ActaNeurol Scand*. 2016 Mar;133(3):183-91. Epub 2015 May 26

Gajofatto A, Turatti M, Monaco S, Benedetti MD. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. *Drug Healthc Patient Saf*. 2015 Dec 11;7:157-67

Patti F., Messina S., Amato M.P., et al. **A multicenter, observational study to evaluate the THC:CBD oromucosal spray (Sativex®) effects in a large population of Multiple Sclerosis patients: SA.FE. study, an Italian Experience. *J NeurolNeurosurg Psychiatry*2016;87(9):944-51**

Calabrese M, Castellaro M, Bertoldo A, et al. **Epilepsy in multiple sclerosis: The role of temporal lobe damage. *MultScler*. 2017 Mar;23(3):473-482**

Gajofatto A, Turatti M, Benedetti MD. Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. *Expert Rev Neurother*. 2017 Apr;17(4):393-406

Farina G, Magliozzi R, Pitteri M, et al. **Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. *J Neuroinflammation*. 2017 Feb 21;14(1):40.**

Firma